M.DrangaM.CardoneanuA.PrelipceanC
Be the first to read: Authors: Giuseppe Consorti, Enrico Betti, Mariagrazia Paglianiti, Lisa Catarzi, Gabriele Monarchi, Massimiliano Gilli, Stefania Troise, Carlos Miguel Chiesa-Estomba, Luigi Angelo Vaira and Giulio Cirignaco
J Am Diet Assoc
Owing to its unique structure and mode of action, SS-31 demonstrates potential therapeutic value across cardiovascular diseases, neurodegenerative disorders, kidney injury, and myopathies associated with mitochondrial dysfunction 1-6
By following the guidelines outlined in this article, researchers can ensure that their peptides remain stable and effective for their intended use